Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Italy Fines Apple €98.6 Million Over App Store Dominance 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
 Securities Case - EconoTimes)
NEW YORK, Dec. 12, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 9, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against ProNAi Therapeutics, Inc. (“ProNAi” or the “Company”) (NASDAQ:DNAI). The class action is on behalf of a class consisting of all persons who purchased ProNAi common stock between July 15, 2015 and June 6, 2016, inclusive (the “Class Period”). ProNAi investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3032-pronai-therapeutics-inc-dnai.html.
ProNAi is a clinical stage oncology company with a focus on pioneering a novel class of therapeutics based on its proprietary DNA interference (“DNAi”) technology platform. Until recently, the Company had only one product candidate – PNT2258, which was purportedly designed to target cancers that overexpress B-cell lymphoma such as Hodgkin’s lymphomas and non-Hodgkin lymphoma.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that the Wolverine and Brighton Phase 2 trials of PNT2258 would fail to prove the efficacy and safety of PNT2258 by meeting its primary or secondary endpoints.
On June 6, 2016, the Company issued a press release announcing interim data for the two Phase 2 trials and revealed that PNT2258 had failed to produce sufficient efficacy results to justify its continued clinical development. On this news, the price of ProNAi common stock declined more than 67%.
What You Can Do
If you purchased ProNAi shares, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
